PoC - Physics of Cancer - Annual Symposium
Go Back
Contributed Talk, Saturday, 09:30 – 09:45  
Development of a novel biosensoric screening system for direct chemosensitivity testing on tumour biopsy material

Sarah Pönick1, Heinz-Georg Jahnke1, Jan Maschke2, Michael Kendler3, Jan C. Simon3, Andrea A. Robitzki1
 
1
 Center for Biotechnology and Biomedicine (BBZ), Molecular biological-biochemical Processing Technology, Deutscher Platz 5, 04103 Leipzig, Germany
2
 Department of Dermatology, Städtisches Klinikum Görlitz gGmbH, Germany
3 Dermatology, Venereology and Allergology Clinic, University Hospital Leipzig, Germany

Contact:  | Website
Today cancer is the second most common cause of death. Due to the fact that each tumour has its own characteristics concerning genetic properties and sensitivity to active pharmaceutical ingredients (API), there is a strong demand for personalized therapies. In this context we developed a screening system that allows direct testing of chemotherapeutics on tumour biopsy material.
Using impedance spectroscopy as a non-invasive, label-free detection technique in combination with our self-developed 3D microcavity array we are able to monitor chemotherapeutic efficiency for more than four days. More strikingly, with our developed screening platform we could minimize the needed tumour material. Therefore, we are now able to receive up to 300 samples from one primary tumour or metastasis respectively. Starting with biopsies from melanoma, we used the isolated fragments to screen a panel of six common used cytostatica. Additionally, we established protocols for the detection of b-raf and c-kit mutations for analysis of tumour heterogeneity and patient dependent target validation of novel APIs like the kinase inhibitors PLX4032 and Imatinib. 
We already measured about ten metastases and three primary tumours. Our impedimetric analysis revealed a specific response pattern for each tumour. The incubation with chemotherapeutics for example cis-platin induced degeneration in one tumour sample while there was no cytostatic effect or even increased proliferation in the other biopsies. 
Regarding the chip-based chemosensitivity screening using viable melanoma biopsies we could quantitatively determine the efficiency and/or efficacy of chemotherapeutics reflecting the individual patient dependent response to the tested drugs. 
University of Leipzig  |  Faculty of Physics and Earth Sciences  |  Institute of Experimental Physics I  |  Soft Matter Physics Division
© 2011 Physics of Cancer | Soft Matter Physics Division, University of Leipzig. Imprint & Disclaimer